XML 114 R78.htm IDEA: XBRL DOCUMENT v3.20.4
Collaborative Arrangements and Licensing Agreements, Novartis (Details)
$ in Thousands, shares in Millions
3 Months Ended 12 Months Ended
Mar. 31, 2019
USD ($)
Jun. 30, 2017
USD ($)
Mar. 31, 2017
USD ($)
PerformanceObligation
shares
Dec. 31, 2020
USD ($)
Dec. 31, 2019
USD ($)
Dec. 31, 2018
USD ($)
Collaborative Arrangement and Licensing Agreement [Abstract]            
Revenue       $ 729,264 $ 1,122,599 $ 599,674
Licensing and Other Royalties [Member]            
Collaborative Arrangement and Licensing Agreement [Abstract]            
Revenue       8,117 17,205 14,755
R&D Revenue [Member]            
Collaborative Arrangement and Licensing Agreement [Abstract]            
Revenue       364,565 770,149 $ 344,752
Novartis [Member]            
Collaborative Arrangement and Licensing Agreement [Abstract]            
Upfront payment received     $ 75,000      
Maximum amount of payments receivable for milestones       675,000    
Maximum amount of payments receivable for development milestones       25,000    
Maximum amount of payments receivable for regulatory milestones       290,000    
Maximum amount of payments receivable for commercialization milestones       360,000    
Cumulative payments received       $ 249,000    
Royalty percentage received on sales of drug       20.00%    
Next prospective payment       $ 25,000    
Shares issued (in shares) | shares     1.6      
Proceeds from sale of common stock     $ 100,000      
Additional amount of common stock required to be purchased     $ 50,000      
Proceeds from sale of common stock to Novartis in a private placement   $ 50,000        
Number of separate performance obligations | PerformanceObligation     4      
Transaction price     $ 108,400      
Premium received on shares issued     28,400      
Potential premium received if common stock is purchased in the future     5,000      
Deferred revenue       $ 0 $ 0  
Novartis [Member] | Revenue [Member] | Strategic Partner [Member]            
Collaborative Arrangement and Licensing Agreement [Abstract]            
Concentration percentage       0.00% 17.00% 8.00%
Novartis [Member] | Licensing and Other Royalties [Member]            
Collaborative Arrangement and Licensing Agreement [Abstract]            
Revenue $ 150,000          
Novartis [Member] | R&D Services for Pelacarsen [Member]            
Collaborative Arrangement and Licensing Agreement [Abstract]            
Transaction price     64,000      
Novartis [Member] | R&D Services for IONIS-APOCIII-L [Member]            
Collaborative Arrangement and Licensing Agreement [Abstract]            
Transaction price     40,100      
Novartis [Member] | Pelacarsen API [Member]            
Collaborative Arrangement and Licensing Agreement [Abstract]            
Transaction price     1,500      
Novartis [Member] | IONIS-APOCIII-L API [Member]            
Collaborative Arrangement and Licensing Agreement [Abstract]            
Transaction price     $ 2,800      
Novartis [Member] | R&D Revenue [Member]            
Collaborative Arrangement and Licensing Agreement [Abstract]            
Revenue       $ 1,000 $ 187,400 $ 50,600